国药一致前三季度归母净利润9.57亿元，同比下降10.18%

Core Viewpoint - The company reported a decline in both revenue and net profit for the first three quarters of 2025, indicating ongoing challenges in the distribution and retail sectors [1] Financial Performance - The company achieved a total revenue of 55.124 billion yuan, a year-on-year decrease of 2.38% [1] - The net profit attributable to shareholders was 0.957 billion yuan, down 10.18% year-on-year, with basic earnings per share decreasing by 9.95% [1] Distribution Segment - The distribution segment generated revenue of 40.594 billion yuan, reflecting a slight decline of 0.59% year-on-year [1] - Net profit from the distribution segment was 0.723 billion yuan, a decrease of 7.32% compared to the previous year [1] - Despite ongoing policy and market competition pressures, the company managed to stabilize distribution revenue through continuous business structure optimization [1] Retail Segment - The retail segment reported revenue of 15.226 billion yuan, which is a year-on-year decline of 7.14% [1] - The net profit for the retail segment was 0.013 billion yuan, showing a significant increase of 133.91% year-on-year [1]